Popular Trials
Cholates for Liver Disease
Recruiting1 awardPhase 2
Dallas, Texas
This trial aims to improve the evaluation of patients with advanced liver disease. Currently, the assessment is limited to imaging, liver function tests, and liver biopsy. However, with advancements in treatments and liver transplantation
Plasma Expander
Albumin for Liver Cirrhosis
Recruiting0 awardsPhase 2
West Haven, Connecticut
This trial aims to study the effects of albumin on increasing urine production in patients with liver disease and fluid retention. It will also look at how albumin may help prevent complications like kidney injury after treatment
Contrast Agent
AMRI vs. Ultrasound for Liver Cancer Surveillance
Recruiting3 awardsPhase 4
La Jolla, California
This trial compares the use of gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for the screening and surveillance of subjects with liver cirrhosis who are at risk for developing hepatocellular carcinoma (HCC).
Popular Filters
Trials for Liver Cirrhosis Patients
SGLT2 Inhibitor
Zibotentan + Dapagliflozin for Liver Cirrhosis
Recruiting0 awardsPhase 2
Birmingham, Alabama
This trial is testing a combination of two drugs, zibotentan and dapagliflozin, and also dapagliflozin alone. It targets people with liver disease (cirrhosis) that causes high blood pressure in the liver's veins. The treatment aims to lower this high blood pressure and improve liver health. Dapagliflozin is a medication that has been shown to reduce cardiovascular death and heart failure.
Procedure
TIPS Procedure for Liver Cirrhosis and Muscle Loss
Recruiting1 awardPhase < 1
Portland, Oregon
This trial will test whether TIPS creation leads to improved muscle mass, body composition and muscle function within the first 12 months after the procedure compared to a control group without TIPS, and whether these changes improve liver disease outcomes in patients awaiting liver transplantation.
Trials for Idiopathic Pulmonary Fibrosis Patients
Behavioural Intervention
Communication Intervention for Dementia
Recruiting1 award12 criteria
Seattle, Washington
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Behavioural Intervention
Yoga for Idiopathic Pulmonary Fibrosis
Recruiting1 award
Seattle, Washington
This trial will investigate if doing yoga exercises made for patients with Idiopathic Pulmonary Fibrosis can improve their quality of life. Participants will be split in half, with one group doing yoga and the
Trials for CFTR Positive Patients
Angiotensin II Receptor Blocker
Losartan for Cystic Fibrosis
Recruiting1 awardPhase < 1
Kansas City, Kansas
This trial is testing losartan, a blood pressure medication, to see if it can help clear mucus from the lungs of cystic fibrosis patients who can't use current treatments. These patients need alternative treatments because they don't respond to existing options. Losartan may reduce lung inflammation, making it easier for them to breathe.
GLP-1 Agonist
GLP-1 Agonist Therapy for Cystic Fibrosis-related Diabetes
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial looks at whether a weekly injection of a medication called dulaglutide can help improve early-phase insulin secretion and glucose tolerance in people with cystic fibrosis-related diabetes.
Gene Therapy
Gene Therapy (4D-710) for Cystic Fibrosis
Recruiting1 awardPhase 1 & 2
Kansas City, Kansas
This trial is testing a new gene therapy called 4D-710 in adults with cystic fibrosis who can't use standard treatments. The goal is to see if it is safe and effective. 4D-710 is part of a new generation of AAV vectors being developed for cystic fibrosis gene therapy.
Phase 3 Trials
Statin
Simvastatin for Liver Cirrhosis
Recruiting1 awardPhase 3
San Francisco, California
This trial tests if simvastatin can prevent serious liver problems in U.S. Veterans with early-stage liver damage. Simvastatin not only lowers cholesterol but also helps protect the liver from further damage and reduces the risk of severe liver issues. Statins, including simvastatin, have been increasingly recognized for their potential benefits in treating chronic liver diseases, including cirrhosis, by reducing portal pressure and protecting against liver damage.
Galectin Inhibitor
Belapectin for NASH Cirrhosis
Recruiting0 awardsPhase 2 & 3
Birmingham, Alabama
This trial is testing belapectin, a medication aimed at helping people with a severe liver condition called NASH cirrhosis. The study focuses on patients who have high blood pressure in their liver but no swollen veins in their esophagus. Belapectin works by reducing liver inflammation and scarring, which can improve liver function and reduce health problems.
Thyroid Hormone Receptor Agonist
Resmetirom for NASH Cirrhosis
Recruiting1 awardPhase 3
North Little Rock, Arkansas
This trial tests a daily pill called resmetirom for people with a stable form of liver disease not caused by alcohol. The goal is to see if the drug can improve liver function and reduce liver fat, thereby preventing serious complications. Resmetirom has been tested in previous studies for the treatment of liver disease.
Antibiotic
Rifaximin for Hepatic Encephalopathy
Recruiting1 awardPhase 3
New Orleans, Louisiana
This trial tests if rifaximin, an oral antibiotic, can delay brain problems in patients with liver cirrhosis and controlled fluid buildup by reducing harmful gut bacteria. Rifaximin has been shown to reduce the recurrence of brain-related issues and related hospitalizations.
Namodenoson for Liver Cancer
Recruiting1 awardPhase 3
Dallas, Texas
This trial tests an oral medication on patients with advanced liver cancer who have not responded to previous treatments. The goal is to see if this medication can slow down or stop the growth of cancer cells in the liver. The medication is being developed to treat liver cancer, where longer survival was observed in patients with advanced liver disease.
Trials With No Placebo
Procedure
TIPS Procedure for Liver Cirrhosis and Muscle Loss
Recruiting1 awardPhase < 1
Portland, Oregon
This trial will test whether TIPS creation leads to improved muscle mass, body composition and muscle function within the first 12 months after the procedure compared to a control group without TIPS, and whether these changes improve liver disease outcomes in patients awaiting liver transplantation.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.